IDEAYA Biosciences, Inc. (IDYA)
IDYA moved a median of +0.10% 30 minutes after news, and +0.46% by the close. How IDYA actually reacts to news — the realized, point-in-time move the market made, measured across 359 labeled events over the last three years with zero look-ahead.
IDYA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.16% | 59% | 358 |
| 30-min | +0.10% | 53% | 359 |
| 60-min | +0.07% | 51% | 359 |
| to close | +0.46% | 56% | 359 |
| Middle 50% of IDYA reactions | -0.92% to +1.12% |
|---|---|
| Median reaction (30-min) | +0.10% |
| Measured reactions | 359 |
Half of all IDEAYA Biosciences, Inc. news events land between -0.92% and +1.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IDYA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 38 | -0.98% | 34% | -0.94% |
| Rating reiterations | 113 | 0.00% | 49% | -0.32% |
| Price-target raises | 26 | +0.11% | 54% | +0.00% |
| Price-target cuts | 10 | +0.02% | 50% | -0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IDYA ranks against every other measured name →
That’s how IDYA usually reacts — get an email when it moves on news →Email me when IDYA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IDYA's baseline. Nothing else.
Recent IDYA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma | Press release | PR Newswire | +0.36% | — | |
| IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development | Press release | PR Newswire | -0.44% | +5.41% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.03% | -0.19% | |
| IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma | Press release | PR Newswire | -0.05% | -1.26% | |
| IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences | Press release | PR Newswire | +0.15% | +0.25% | |
| The Melanoma Research Foundation Welcomes Back Jacquie Palisi, Colorado Native and Melanoma Warrior, as Emcee of the 15th Annual Denver Gala | Press release | PR Web | +0.07% | +0.40% | |
| IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer | Press release | PR Newswire | +0.23% | +0.91% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.26% | -2.50% | |
| IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer | Press release | PR Newswire | -2.41% | -0.36% | |
| Form 10-Q IDEAYA Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.92% | -0.63% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | +0.06% | |
| IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -1.41% | +0.06% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -1.54% | -2.39% | |
| IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers | Press release | PR Newswire | -0.88% | +1.13% | |
| IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | Press release | PR Newswire | +0.51% | +2.33% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.77% | +0.38% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +2.28% | |
| IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors | Press release | PR Newswire | -0.89% | +1.56% | |
| IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers | Press release | PR Newswire | +0.80% | +2.68% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +5.25% | |
| IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | Press release | PR Newswire | +0.47% | +5.25% | |
| IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | +2.16% | -7.51% | |
| IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants | Press release | PR Newswire | +2.16% | -7.51% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | +2.23% | |
| IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer | Press release | PR Newswire | +0.07% | +2.23% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -2.48% | |
| IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO | Press release | PR Newswire | +0.16% | +1.83% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.36% | +0.44% | |
| IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference | Press release | PR Newswire | -1.85% | +0.69% | |
| Form 10-Q IDEAYA Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.96% | +1.77% | |
| Form 8-K IDEAYA Biosciences, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +1.39% | +2.42% | |
| Form S-3ASR IDEAYA Biosciences, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -0.96% | +1.77% | |
| IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +1.39% | +2.42% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | +0.72% | -2.86% | |
| Form DEFA14A IDEAYA Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.72% | -2.86% | |
| IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program | Press release | PR Newswire | +0.90% | +2.18% | |
| Form ARS IDEAYA Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.90% | +2.18% | |
| Form DEF 14A IDEAYA Biosciences, Inc. For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +0.90% | +2.18% | |
| IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma | Press release | PR Newswire | +0.56% | -0.38% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +4.52% | -5.42% | |
| IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma | Press release | PR Newswire | +4.52% | -5.42% | |
| IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 | Press release | PR Newswire | +4.52% | -5.42% | |
| Form 8-K IDEAYA Biosciences, Inc. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -0.57% | +0.26% | |
| IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer | Press release | PR Newswire | -0.78% | -2.77% | |
| IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma | Press release | PR Newswire | -0.66% | +3.15% | |
| IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | PR Newswire | -0.79% | -4.30% | |
| IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial | Press release | PR Newswire | -3.68% | -3.33% | |
| IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs | Press release | PR Newswire | -0.17% | -2.86% | |
| IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update | Press release | PR Newswire | +3.60% | +5.19% | |
| Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 | Press release | Business Wire | +0.63% | +3.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IDYA section they belong to.
Where else IDYA is measured.
IDYA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is IDEAYA Biosciences, Inc.'s median reaction calculated?
Every labeled IDYA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 359 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of IDYA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IDYA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.